---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032184"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2025-10-29T23:59:59+00:00"
generated_at: "2026-05-17T01:34:02.697972+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# CervoMed appoints former McKinsey Senior Partner David Quigley to Board

## Summary
- David Quigley appointed to board effective Oct 27, 2025; board expanded from 7 to 8 members.
- Quigley was McKinsey Senior Partner (2010-2025) leading Private Capital and Life Sciences practices.
- Granted option to buy 16,200 shares at $7.02, vesting in 36 equal monthly installments.
- Company expects FDA feedback on Phase 3 trial design for neflamapimod in DLB in Q4 2025.

## SEC filing metadata
- accession: 0001437749-25-032184
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2025-10-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/0001437749-25-032184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774925032184/crvo20251029c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032184
- JSON: https://secwatch.observer/filing/0001437749-25-032184.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032184.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.